IBM's Partner and Quantum News Flow Into a Single October Verdict

Fortra launched Continuity Care for IBM Power and IBM i, and IBM cleared DARPA's Quantum Benchmarking Stage C. Q3 results land October 21.

Two separate announcements landed in IBM's orbit this week — one from a partner, one from a federal research agency — and both point investors toward the same date on the calendar. Fortra rolled out a cyber-resilience service for IBM Power and IBM i environments, while IBM confirmed it had cleared the third phase of DARPA's Quantum Benchmarking Initiative. Neither development, on its own, settles the question that matters most for the equity: whether IBM can convert its recurring software base back into faster growth.

Fortra's Continuity Care: A Partner Win, Not Yet an IBM Win

The new offering, branded Continuity Care, leans on FalconStor technology and bundles backup, recoverability verification, and post-incident restoration. Its options are designed to flex with shifting cyber risks and operational demands, targeting the day-to-day running of existing IBM Power and IBM i estates.

For shareholders, the immediate takeaway is limited. A partner's launch does not by itself prove incremental recurring revenue for IBM. The distinction between a broader service catalog for customers and a measurable contribution to IBM's own top line is one analysts will want to test in upcoming filings — specifically, whether IBM discloses security- and resilience-related recurring revenue tied to these environments.

That framing matters because recurring revenue already carries enormous weight at IBM. Roughly 80% of annual software revenue was recurring in the second quarter of 2026, and software accounted for just under 45% of total company revenue. Such a mix makes the trajectory of software contracts the single most-watched line item. Additional partner offerings can widen the menu for customers, but they are no substitute for evidence that IBM itself is accelerating.

The Growth Gap Behind the Recurring Base

The second-quarter numbers laid bare the tension. Software revenue rose 5%, yet organic growth was flat. Management trimmed its full-year software growth guidance to 6–8%, even as it continues to hold out a long-term target of double-digit expansion. That leaves a visible gap between near-term delivery and the longer-range ambition.

What investors are watching now is whether IBM can work through delayed deal closures. As of the most recent earnings call, roughly one-third of late large contracts had been completed.

DARPA Stage C: Technical Milestone, Economic Question Mark

On the technology side, IBM said Thursday it had reached Stage C of DARPA's Quantum Benchmarking Initiative, the phase dedicated to independent review of quantum computing technology and its architecture. It is a tangible step for the quantum program, but its meaning stays technical: entering the review phase is neither a finished assessment nor proof of commercial demand. Those layers deserve to be judged separately.

A more application-oriented effort arrived on October 7, when IBM and SAP unveiled IBM Ready for SAP Solutions, aimed at helping midsize and fast-growing organizations modernize cloud ERP systems while building an AI-ready digital foundation. IBM cited a concrete customer case: at Volumetric Building Companies, operational cycle times fell 50% after a three-month SAP cloud ERP transformation. That illustrates what modernization can deliver — though a single example cannot show how broadly such projects will lift demand for IBM's offerings.

One Date, Two Tests

The next financial checkpoint is already set. IBM will report third-quarter 2026 results on October 21, with the accompanying call scheduled for 5:00 p.m. ET. Analysts expect earnings per share of $2.86 on revenue of $16.82 billion.

That print will be the moment when technological progress gets placed alongside business performance. The analyst community remains cautious on near-term execution risks and on the uncertainty over when enterprise spending on AI infrastructure actually translates into demand — a stance reflected in a $240 price target. The stock's 1.8% gain on the day is a positive signal, but it does not dissolve those reservations.

For now, the two announcements sit in the same category: they demonstrate momentum in products and technical milestones without answering the financial question. The verdict that counts will come when IBM reports — and when investors learn whether its recurring software revenue is finally translating into stronger growth.